REPLIMUNE GROUP, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3
REPLIMUNE GROUP, INC. (REPL) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 of $0 for the 12-month period ending 2021-03-31, per its 10-K filed 2021-05-20.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 · last filed 2021-05-20
- REPLIMUNE GROUP, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for the quarter ending 2021-03-31 was $0.00.
- REPLIMUNE GROUP, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for the quarter ending 2020-12-31 was $0.00.
- REPLIMUNE GROUP, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for the quarter ending 2020-09-30 was $0.00.
- REPLIMUNE GROUP, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for the quarter ending 2020-06-30 was $0.00.
- REPLIMUNE GROUP, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for fiscal 2021 was $0.00.
- REPLIMUNE GROUP, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for fiscal 2020 was $0.00.
- REPLIMUNE GROUP, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for fiscal 2019 was $0.00.
- REPLIMUNE GROUP, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers out of level 3 for fiscal 2018 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 12 month |
|---|---|---|---|---|
| 2021-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-20 | $0.00 derived: sum of 2 quarters · filed 2021-05-20 | $0.00 derived: sum of 3 quarters · filed 2021-05-20 | $0.00 10-K · filed 2021-05-20 |
| 2020-12-31 | $0.00 10-Q · filed 2021-02-04 | $0.00 derived: sum of 2 quarters · filed 2021-02-04 | $0.00 10-Q · filed 2021-02-04 | $0.00 derived: sum of 4 quarters · filed 2021-05-20 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 3 quarters · filed 2021-05-20 | $0.00 derived: sum of 4 quarters · filed 2021-05-20 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-07 | $0.00 derived: sum of 2 quarters · filed 2021-05-20 | $0.00 derived: sum of 3 quarters · filed 2021-05-20 | $0.00 derived: sum of 4 quarters · filed 2021-05-20 |
| 2020-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-20 | $0.00 derived: sum of 2 quarters · filed 2021-05-20 | $0.00 derived: sum of 3 quarters · filed 2021-05-20 | $0.00 10-K · filed 2021-05-20 |
| 2019-12-31 | $0.00 10-Q · filed 2021-02-04 | $0.00 derived: sum of 2 quarters · filed 2021-02-04 | $0.00 10-Q · filed 2021-02-04 | $0.00 derived: sum of 4 quarters · filed 2021-02-04 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 3 quarters · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-07 | $0.00 derived: sum of 2 quarters · filed 2020-08-07 | $0.00 derived: sum of 3 quarters · filed 2020-08-07 | $0.00 derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03 | $0.00 derived: sum of 2 quarters · filed 2020-06-03 | $0.00 derived: sum of 3 quarters · filed 2020-06-03 | $0.00 10-K · filed 2020-06-03 |
| 2018-12-31 | $0.00 10-Q · filed 2020-02-13 | $0.00 derived: sum of 2 quarters · filed 2020-02-13 | $0.00 10-Q · filed 2020-02-13 | $0.00 derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | $0.00 derived: sum of 3 quarters · filed 2019-11-12 | $0.00 derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-14 | $0.00 derived: sum of 2 quarters · filed 2019-08-14 | $0.00 derived: sum of 3 quarters · filed 2019-08-14 | $0.00 derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-06-28 | $0.00 derived: sum of 2 quarters · filed 2019-06-28 | $0.00 derived: sum of 3 quarters · filed 2019-06-28 | $0.00 10-K · filed 2019-06-28 |
| 2017-12-31 | $0.00 10-Q · filed 2019-02-14 | $0.00 derived: sum of 2 quarters · filed 2019-02-14 | $0.00 10-Q · filed 2019-02-14 | |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-14 | $0.00 10-Q · filed 2018-11-14 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-08-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |